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ABSTRACT
FATINI, C., R. GUAZZELLI, P. MANETTI, B. BATTAGLINI, F. GENSINI, R. VONO, L. TONCELLI, P. ZILLI, A. CAPALBO,
R. ABBATE, G. F. GENSINI, and G. GALANTI. RAS genes influence exercise-induced left ventricular hypertrophy: an elite athletes
study. Med. Sci. Sports Exerc., Vol. 32, No. 11, pp. 1868–1872, 2000. Purpose: The association of ACE I/D polymorphism with
changes in LV mass in response to physical training has been observed, but no association has been found with AT1R A1166C
polymorphism. We investigated the ACE I/D, AT1R A1166C, and AT1R CA microsatellite polymorphisms genotype distribution in
elite athletes and whether the presence of AT1R C1166 variant, in addition to ACE D allele affects the training-induced LV mass
alterations in elite trained athletes. Methods: The study population comprised 28 healthy players recruited from an Italian elite male
soccer team and 155 healthy male subjects. LV mass, LV mass adjusted for body surface area, septal thickness, posterior wall,
end-diastolic and end-systolic ventricular dimension, and ejection fraction were determined by echocardiography in pretrained period,
at rest and 7 months later during the training. All subjects were genotyped for ACE I/D, AT1R A1166C, and CA microsatellite
polymorphisms. Results: Training induced an LV mass increase in all but six athletes. The percentage of athletes in whom an increase
of LV mass was found after training was statistically different in relation to the ACE D allele: no increase was observed in three of
24 D allele carriers and in three of four II genotype players (Fisher’s exact test, P 5 0.02). As AT1R is concerned, no increase was
observed in 4 of 15 C allele carriers and in 2 of 13 AA genotype athletes (Fisher’s exact test, P . 0.05). The contemporary presence
of ACE D and AT1R C allele did not affect the changes after training. No difference has been observed in the CA microsatellite marker
allele frequencies between athletes and controls (P 5 0.46). Conclusion: In this study, we provide the evidence that soccer play does
not select athletes on genotype basis. Training-induced LV mass changes in male elite athletes are significantly associated with the
presence of ACE D allele, but not of AT1R C allele. Key Words: RAS POLYMORPHISMS, LEFT VENTRICULAR MASS
The endocrine renin angiotensin system (RAS) playsan important role in controlling the circulatory sys-tem. Genes encoding components of RAS regulate
angiotensin-converting enzyme (ACE) levels, as well as
angiotensin II expression and function. In intron 16 of the
ACE gene, a polymorphism consisting in the presence (in-
sertion) or absence (deletion) of the 287-bp Alu sequence
has been detected. This insertion/deletion (I/D) polymor-
phism accounted for 47% of the total phenotypic serum
ACE variance (12). The D allele of ACE gene I/D poly-
morphism is associated with high ACE levels in ventricular
tissue as well as in the circulation (12). As the presence of
each allele had an additive effect on serum ACE and two
alleles had twice the effect of one, each allele was codomi-
nant. High ACE levels could determine their effects through
changes either in angiotensin II levels or in kinin degrada-
tion. The I/D polymorphism is associated also with concen-
tric left ventricular (LV) remodeling in hypertension (4),
cardiomyopathy (11), and LV hypertrophy (6). The associ-
ation of ACE I/D polymorphism with change in LV mass in
response to physical training has been observed in male
subjects recruited in the Army Training Regiment Bassing-
bourn (7). Moreover, ACE II genotype has been found to be
associated with improved endurance in a limited group of
climbers (9). The final effector of RAS is angiotensin II, a
highly vasoactive and aldosterone-stimulating octapeptide,
which may modulate or induce the growth of vascular
smooth muscle cells (SMC) and cardiomyocytes. In LV
tissue, angiotensin II paracrine and autocrine action modu-
lates myocardial growth through the angiotensin II type 1
receptor (AT1R) (4). ACE is a zinc metallo protease that
inactivates bradykinin by cleaving two carboxy-terminal
dipeptides and suppressing its biological effects. Bradykinin
is a potent vasodilator and inhibitor of SMC proliferation,
0195-9131/00/3211-1868/0
MEDICINE & SCIENCE IN SPORTS & EXERCISE®
Copyright © 2000 by the American College of Sports Medicine
Submitted for publication August 1999.
Accepted for publication February 2000.
1868
which could act through the release of endothelial factors,
including nitric oxide and prostacyclin (16). In the AT1R
gene, within the 39 untranslated region, a polymorphism
consisting in a transversion A3C in position 1166
(A1166C) has been identified; this C1166 variant has been
associated with hypertension in humans (1), but no associ-
ation between AT1R A1166C polymorphism and exercise-
induced LV changes has been observed (8). In the 39 flank-
ing region of the AT1R gene, a fragment comprising highly
informative dinucleotide repeat (CA) was established (2). A
total of 10 alleles were detected (ranging in size from 132 to
146 bp).
Few studies evaluated the role of this highly polymorphic
microsatellite located near the human AT1R gene1 in human
essential hypertension and in athletic performance (5). The
aims of this study were to investigate: 1) the ACE and AT1R
genotype and AT1R gene microsatellite markers distribu-
tion in elite athletes; and 2) whether the presence of AT1R
C1166 variant, in addition to ACE D allele, affects the LV
mass training-induced alterations in elite trained athletes.
METHODS
Subjects. Twenty-eight healthy players recruited from
an Italian elite male soccer team aged between 17 and 29 yr
(mean 20.2 6 4.4) were studied during pretraining period
and after seven months of training (36 h after the last
training section). As controls, we studied 155 healthy male
subjects (mean age 23 6 2.3), untrained students of the
Medical School of the University of Florence. In 28 control
subjects, echocardiographic study was also performed. All
the subjects were Caucasian, nonconsanguineous, and gave
informed consent to genotyping.
Echocardiographic methods. Mono-two-dimensional
echocardiographic examinations were performed using an
Esaote device (AU3–3.5 2.5 MHz probes Esaote Biomedica
Florence, Italy).
Parasternal long axis, short axis, apical four chambers
with aorta and when necessary subcostal views were used.
The interventricular septum and posterior wall thickness,
systolic and diastolic LV dimensions and ejection fraction
were measured, by means of leading edge technique, with
monodimensional echocardiography under two dimensional
guide (15).
Measurements were performed on four to six cycles by
means of a computer-aided method and averaged. Record-
ings were made entirely on videotape and evaluated by two
expert echocardiographers. The intraobserver and interob-
server variability for repeated measurements was assessed
by unpaired Student’s t-test.
LV mass, according to Devereux formula (3), and LV
mass index corrected for the body surface area were calcu-
lated. Ejection fraction was estimated by formula of Tei-
cholz et al. (18).
DNA analysis. Genomic DNA was extracted from pe-
ripheral blood and ACE I/D polymorphism was determined
by primers and PCR conditions previously described by
Rigat et al. (14). DNA was amplified in presence of 5%
dimethylsulfoxide (DMSO) in the reaction mixture at an
annealing temperature of 60°C, for reducing the incidence
of mistyping ID as DD. Fragments of ’190 bp (deletion
allele) and ’490 bp (insertion allele) were separated on a
2% agarose gel, stained with ethidium bromide, and visu-
alized on a UV transilluminator. Moreover, each DD geno-
type was subjected to a second PCR amplification without
the 5% DMSO at an annealing temperature of 67°C and
using a primer pair that recognizes an insertion-specific
sequence, to reduce underestimation of heterozygotes. The
AT1R C1166 variant was analyzed by PCR and restriction
fragment length polymorphism (RFLP) analysis, using
primers and PCR conditions as described by Katsuja et al.




(N 5 155) P
ACE genotype
II 4 (14%) 20 (13%)
ID 12 (43%) 74 (48%)
DD 12 (43%) 61 (39%)




x2 5 0.02 0.88
AT1R genotype
CC 2 (8%) 9 (6%)
AC 13 (46%) 70 (45%)
AA 13 (46%) 76 (49%)





x2 5 0.09 0.76
ACE DD1ID with
AT1R AC1CC
11 (46%) 63 (47%)
ACE DD1ID with
AT1R AA
13 (54%) 72 (53%) 0.94
TABLE 2. LV mass, LV mass index, septal thickness, posterior wall, and end-diastolic dimension in controls and in athletes before and after training.
Controls (N 5 28) Pa (Unpaired t-Test)
Athletes (N 5 28)
Pretraining Pb (Paired t-Test) Post-Training
LV mass (g) 172.5 6 35.6 0.0039 206.03 6 36.7 0.002 229.4 6 47.2
LV mass index (gzm22) 95.1 6 18.4 0.00009 109.5 6 17.6 0.004 120.8 6 22.8
Septal thickness (mm) 8.7 6 1.0 0.08 9.2 6 0.8 0.009 9.8 6 1.1
Posterior wall (mm) 8.7 6 0.8 0.017 9.2 6 0.7 0.82 9.3 6 1.1
End-diastolic dimension (mm) 49.5 6 4.1 0.016 52.2 6 3.8 0.03 53.7 6 3.4
End-systolic dimension (mm) 30.3 6 3.9 0.37 31.2 6 4.1 0.19 32.2 6 3.1
Ejection fraction (%) 68 6 5.1 0.65 69.5 6 6.1 0.86 69.7 6 5.7
a P controls vs pretraining athletes.
b Pretraining vs post-training.
Values are mean 6 SD.
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(9). PCR products were digested by 5 U Dde I at 37°C for
2 h, and the digestion products were separated on 2%
agarose gel and visualized by ethidium bromide. The C1166
variant was identified if digestion of the PCR products was
observed.
Genotyping of a dinucleotide repeat (CA alleles) at the
AT1R locus was performed by primers and PCR conditions
as described by Davies et al. (2). The ATCA1 primer was
end-labeled with (g32 P) dATP using T4 polynucleotide
kinase. Amplification by PCR was carried out in a total
volume of 25 mL. A thermal cycler was used for 30 cycles
of 30 s at 95°C and 20 s at 56°C. The length of each allele
was determined on a 6% denaturing polyacrylamide gel.
Statistical analysis. Allele frequencies were estimated
with the gene counting method. A chi-square test was used
to assess the fit of the observed allele frequencies to the
agreement of the Hardy-Weinberg equilibrium and the dif-
ference in genotype distribution. Differences between pre-
and post-training measurements of LV dimensions and mass
were calculated for each subject. Data were analyzed for the
study population as a whole, and differences in response
between different genotype groups were compared. Pre- and
post-training data were compared using two-tailed paired
t-test. Fisher’s exact test was used to evaluate whether LV
mass and LV mass index after training were associated to
ACE and AT1R genotypes. Values of P , 0.05 were con-
sidered to be statistically significant. Paired and unpaired
t-tests were used as appropriate.
RESULTS
Genotype distribution and allele frequency in athletes
were comparable to those found in controls (Table 1). Pre-
training LV mass was significantly higher in athletes respect
to the controls (Table 2).
The training induced LV mass increase in 22 of 28
athletes. The changes in LV mass, LV mass index, septal
thickness, posterior wall, and end-diastolic dimension after
training are shown in Table 2. A significant difference
between pre- and post-training in LV mass, LV mass index,
septal thickness, and end-diastolic dimension, but not in
posterior wall, end-systolic dimension, and LV function in
relation to ACE genotype, was found (Tables 3 and 4). A
significant difference between pre- and post-training in re-
lation to AT1R genotype was found only in LV mass and
LV mass index (Tables 3 and 4). The entity of changes after
training was statistically different among ACE D allele
carriers in LV mass, LV mass index, septal thickness, and
end-diastolic dimension (Table 3 and 4). The evaluation of
mean of difference between ACE II and ACE D allele
carriers was statistically significant in LV mass (unpaired
TABLE 3. LV mass, LV mass index, end-systolic dimension, and ejection fraction








All 206 6 36.7 229.5 6 47.2 0.002
ACE genotype
II 201.5 6 7.5 195.5 6 30.3 26 0.71
ID1DD 206.8 6 39.6 235.1 6 47.6 28.3 ,0.0001
AT1R genotype
AA 207.7 6 36.4 230.7 6 42.6 0.0002
AC1CC 204.5 6 38.1 228.3 6 52.4 0.04
DD1ID/AA 208.2 6 35.2 230.8 6 42.6 0.002
DD1ID/AC1CC 205.6 6 44.9 240.3 6 54.5 0.005
LV mass index (gzm22)
All 109.5 6 17.6 120.8 6 22.8 0.005
ACE genotype
II 107.8 6 5.1 104.2 6 15.2 23.5 0.71
ID1DD 109.8 6 18.7 123.8 6 22.6 11.9 0.005
AT1R genotype
AA 111.3 6 19.2 122.7 6 22.6 0.0007
AC1CC 108.0 6 16.7 119.5 6 22.7 0.06
DD1ID/AA 114.1 6 19.2 122.8 6 22.6 0.0008
DD1ID/AC1CC 108.7 6 19.8 126.8 6 23.4 0.006
End-systolic dimension
All 31.2 6 4.1 32.2 6 3.1 0.19
ACE genotype
II 31.6 6 3.2 33.9 6 3.02 22.4 0.48
ID1DD 31.2 6 4.3 31.9 6 3.1 20.7 0.31
AT1R genotype
AA 31.4 6 4.7 32.1 6 3.3 0.50
AC1CC 31.1 6 3.7 32.3 6 3.1 0.49
DD1ID/AA 31.4 6 4.7 32.1 6 3.3 0.49
DD1ID/AC1CC 30.8 6 3.9 31.7 6 2.9 0.49
Ejection fraction
All 69.5 6 6.1 69.7 6 5.7 0.86
ACE genotype
II 68.2 6 4.4 65.7 6 5.7 22.5 0.6
ID1DD 69.7 6 6.4 70.4 6 5.5 20.7 0.65
AT1R genotype
AA 69.6 6 6.5 69.8 6 5.9 0.94
AC1CC 69.3 6 5.9 69.7 6 5.6 0.57
DD1ID/AA 69.6 6 6.5 69.8 6 5.9 0.94
DD1ID/AC1CC 69.7 6 6.6 71.1 6 5.05 0.57
Values are mean 6 SD. TABLE 4. Septal thickness, posterior wall, and end-diastolic dimension in relation to








All 9.2 6 0.8 9.8 6 1.1 0.81
ACE genotype
II 9.1 6 0.4 8.6 6 0.5 20.4 0.07
ID1DD 9.2 6 0.8 10.0 6 1.2 0.79 0.004
AT1R genotype
AA 9.2 6 0.9 9.9 6 1 0.09
AC1CC 9.1 6 0.7 9.7 6 1.3 0.06
DD1ID/AA 9.2 6 0.9 9.9 6 1 0.09
DD1ID/AC1CC 9.1 6 0.8 10.1 6 1 0.014
Posterior wall (cm)
All 9.2 6 0.7 9.3 6 1.1 0.81
ACE genotype
II 9.2 6 0.9 8.5 6 0.9 20.7 0.15
ID1DD 9.2 6 0.7 9.4 6 1 20.2 0.44
AT1R genotype
AA 9.3 6 0.7 9.2 6 1 0.90
AC1CC 9.2 6 0.8 9.3 6 1.3 0.86
DD1ID/AA 9.3 6 0.7 9.2 6 1 0.90
DD1ID/AC1CC 9.2 6 0.8 9.6 6 1.2 0.20
End-diastolic dimension
All 52.2 6 3.8 53.7 6 3.4 0.08
ACE genotype
II 52.2 6 2.6 53.6 6 2.9 21.3 0.64
ID1DD 52.1 6 3.9 53.7 6 3.5 1.6 0.04
AT1R genotype
AA 52.1 6 4.3 53.7 6 3.6 0.14
AC1CC 52.3 6 3.7 53.9 6 3.4 0.21
DD1ID/AA 52.1 6 4.3 53.7 6 3.6 0.13
DD1ID/AC1CC 52.2 6 3.9 53.9 6 3.4 0.16
Values are mean 6 SD.
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t-test) (Table 5). The percentage of athletes in whom an
increase of LV mass and LV mass index after training was
found was significantly higher (Fisher’s exact test, P 5
0.02) in ACE DD and ID genotype in comparison with ACE
II genotype: an increase was observed in 21 of 24 DD1ID,
and in one of four II genotype carriers (Fig. 1).
As AT1R genotype is concerned, no increase was ob-
served in 4 of 15 AC1CC and in 2 of 13 AA genotype
carriers (Fisher’s exact test 5 0.64). In athletes with the
contemporary presence of ACE D and AT1R C allele, the
increase in LV mass after the training period was more
elevated, although it did not reach the statistical significance
(P 5 0.063) in comparison with DD1ID/AA athletes. The
genotype distribution and allele frequency were in agree-
ment with the Hardy-Weinberg equilibrium.
No significant difference in the distribution of the AT1R
gene microsatellite marker frequencies between athletes and
controls has been found (x2 57.703, P 5 0.46) (Fig. 2).
DISCUSSION
This is the first study investigating RAS genes in athletes,
which suggests that the soccer play does not select athletes
on a genotypic basis. In fact, our data show that ACE and
AT1R genotype distribution and allele frequency observed
in elite athletes are comparable to those observed in the
general population. These results seem at variance with the
findings obtained in high altitude mountaineers in whom the
observed high percentage of II genotype has been impli-
cated in the increase of the cardiac output and muscle
capillary density (10). However, these two physical perfor-
mances are quite dissimilar.
This report indicates that ACE genotype influences the
exercise-induced ventricular growth in elite athletes, as pre-
viously found in untrained young male subjects (11). The
role of the ACE I/D polymorphism on the LV growth may
be mediated through ACE via alterations in tissue kinin
metabolism or effects on angiotensin II synthesis. Increased
cardiac ACE activity has been associated with increased
local generation of angiotensin II when isolated hypertro-
phied rat hearts were perfused with angiotensin I (17), and
increased angiotensin II levels have been associated with
ACE D allele (13). However, ACE is not the only rate-
limiting step in basal angiotensin II generation; in fact, a
discovered non-ACE chymase peptidase, found in the car-
diac membrane preparations from human hearts, has been
shown to generate angiotensin II from angiotensin I in an in
vitro system (19). Angiotensin II might become a rate-
limiting step in hypertrophic stimulation and ACE genotype
might be correlated with physiological and pathological
hypertrophy. The exercise-related LV growth is associated
with improved myocardial function and the ACE associa-
tion with physiological hypertrophy is consistent with a role
for paracrine renin-angiotensin system in the control of LV
growth.
Regarding to the association between AT1R genotypes
and LV hypertrophy, we found no effect from AT1R alleles
on exercise-induced ventricular mass; however, our results,
although not statistically significant due to the sample size,
suggest that the contemporary presence of ACE D and
AT1R C alleles affects the exercise-related LV hypertrophic
response. This study did not identify the AT1R CA micro-
satellite as a genetic marker for soccer play, according to
Gayagay et al. (5)
Larger studies addressed not only to ACE, but also to
AT1R polymorphisms, which mediate the angiotensin II
effects, may offer new insights in the knowledge of the
mechanism involved in the physiology and pathophysiology
of myocardial exercise-induced hypertrophy.
Address for correspondence: Francesca Gensini, Istituto di
Clinica Medica Generale e Cardiologia, University of Florence, V. le
Morgagni, 85, 50134 Florence, Italy; E-mail: r.abbate@dfc.unifi.it.
Figure 1—Athletes with training-induced left ventricular mass in-
crease in relation to ACE genotype.
Figure 2—AT1R gene microsatellite markers allele frequencies.




ACE genotype 26 6 14.9 28.3 6 5.2 0.02
LV mass index
ACE genotype 23.5 6 8.7 11.9 6 3.8 0.13
Septal thickness
ACE genotype 20.37 6 0.1 0.79 6 0.2 0.07
Posterior wall
ACE genotype 20.2 6 0.5 0.17 6 0.2 0.52
End-diastolic dimension
ACE genotype 1.37 6 2.6 1.36 6 0.7 0.99
End-systolic dimension
ACE genotype 2.37 6 2.9 0.60 6 0.7 0.42
Ejection fraction
ACE genotype 22.5 6 4.3 0.71 6 1.5 0.44
Values are mean 6 SD.
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